AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 203308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31688450 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate 3-Month (PP3M)
Number of subjects: 1307
Study 31688450 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate 1-Month (PP1M)
Number of subjects: 1307
Study 31688450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1307
Study 28167193 — intervention group
Group type: EXPERIMENTAL
Intervention: Scapula Backward Tipping Test (SBTT)
Number of subjects: 30
Study 26743288 — intervention group
Group type: EXPERIMENTAL
Intervention: Different oral hygiene maintenance programs
Number of subjects: 36
Study 26743288 — intervention group
Group type: COMPARATOR
Intervention: Fixed orthodontic treatment with proper oral hygiene
Number of subjects: 36
Study 23322707 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT) imaging
Number of subjects: 48
Study 23322707 — intervention group
Group type: COMPARATOR
Intervention: Conventional clinical assessment using the OM assessment scale (OMAS)
Number of subjects: 48
Study 21689069 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of zoledronic acid
Number of subjects: 46
Study 21689069 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride (control)
Number of subjects: 46
Study 19332467 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 800
Study 19332467 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study 16835383 — intervention group
Group type: EXPERIMENTAL
Intervention: CHVP plus interferon alpha (12 cycles for 18 months)
Number of subjects: 401
Study 16835383 — intervention group
Group type: COMPARATOR
Intervention: CHOP followed by high-dose therapy with ASCT (4 cycles)
Number of subjects: 401
Study 16835383 — intervention group
Group type: EXPERIMENTAL
Intervention: CHVP plus interferon alpha
Number of subjects: 401
Study 16835383 — intervention group
Group type: COMPARATOR
Intervention: CHOP followed by high-dose therapy with ASCT
Number of subjects: 401
Study 16835383 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with complete response at end of induction therapy
Number of subjects: 401
Study 12697371 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg/day elemental calcium and 800 IU/day vitamin D(3) supplementation
Number of subjects: 3270
Study 12697371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3270
Study 11007833 — intervention group
Group type: EXPERIMENTAL
Intervention: High-UFH regimen (HHR) at 90 IU/kg body-weight (b.w.)
Number of subjects: 10
Study 11007833 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-UFH regimen (LHR) at 50 IU/kg b.w.
Number of subjects: 10
Study 11007833 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) at 85 IU/kg b.w. (HHR)
Number of subjects: 10
Study 11007833 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) at 45 IU/kg b.w. (LHR)
Number of subjects: 10
Study 9068336 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol induction followed by a standard propofol infusion
Number of subjects: 48
Study 9068336 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane maintenance after propofol induction
Number of subjects: 48
Study 8437256 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (400 mg)
Number of subjects: 125
Study 8437256 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg)
Number of subjects: 125
Study 8437256 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin (800 mg)
Number of subjects: 125
Study 8437256 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial treatment (2-tablet quinolone treatment)
Number of subjects: 125
Study 8437256 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial treatment in premenopausal group
Number of subjects: 125
Study 8437256 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial treatment in postmenopausal group
Number of subjects: 125
Study 3093022 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms 24R,25(OH)2D3 daily
Number of subjects: 58
Study 3093022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 3093022 — intervention group
Group type: EXPERIMENTAL
Intervention: 24R,25(OH)2D3 treatment
Number of subjects: 58
Study 30427894 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Functional Exercise (HIFE) Program
Number of subjects: 186
Study 30427894 — intervention group
Group type: COMPARATOR
Intervention: Seated social group activity
Number of subjects: 186
Study 26862746 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-abrasivity gel-to-foam fluoride toothpaste (1,450 ppm NaF)
Number of subjects: 56
Study 26862746 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-abrasivity gel-to-foam fluoride toothpaste (1,450 ppm NaF)
Number of subjects: 56
Study 26862746 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference toothpaste (1,450 ppm NaF)
Number of subjects: 56
Study 26862746 — intervention group
Group type: COMPARATOR
Intervention: Placebo toothpaste (0 ppm fluoride)
Number of subjects: 56
Study 24815910 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 30, 50, and 70 mg/day
Number of subjects: 265
Study 24815910 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 265
Study 22650126 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy laser irradiation on acupoint and external auditory canal combined with auricular point sticking (APS)
Number of subjects: 258
Study 22650126 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture at the same acupoints as those in observation group 1
Number of subjects: 258
Study 22650126 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 258
Study 22650126 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy laser irradiation and APS
Number of subjects: 258
Study 22650126 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 258
Study 20435265 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position BMD measurement (adjusted for sitting equivalent)
Number of subjects: 82
Study 20435265 — intervention group
Group type: COMPARATOR
Intervention: Sitting position BMD measurement
Number of subjects: 82
Study 18661187 — intervention group
Group type: EXPERIMENTAL
Intervention: MT1-MMP-positive expression in peripheral blood
Number of subjects: 810
Study 18661187 — intervention group
Group type: EXPERIMENTAL
Intervention: MT1-MMP-positive expression in bone marrow
Number of subjects: 810
Study 15878099 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated fractionation (AF) - 60.8 Gy in 32 fractions over 26 days, two fractions per day (1.8 Gy and 2.0 Gy) with a 6h gap, 1 week treatment gap after first 12 fractions.
Number of subjects: 229
Study 15878099 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation (CF) - 64 Gy in 32 fractions over 45 days, one fraction per day, 5 days per week.
Number of subjects: 229
Study 15878099 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated fractionation (AF)
Number of subjects: 229
Study 15878099 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation (CF)
Number of subjects: 229
Study 11955466 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) - 10-20 treatments, 10 Hz, 110% motor threshold applied to the left dorsolateral prefrontal cortex for a total of 10,000-20,000 stimulations
Number of subjects: 25
Study 11955466 — intervention group
Group type: COMPARATOR
Intervention: Electroconvulsive therapy (ECT) - 4-12 treatments
Number of subjects: 25
Study 11955466 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 25
Study 11955466 — intervention group
Group type: COMPARATOR
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 25
Study 9564057 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH analog
Number of subjects: 17
Study 9564057 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 17
Study 7634871 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline 3 mg/kg
Number of subjects: 24
Study 7634871 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline 6 mg/kg
Number of subjects: 24
Study 7634871 — intervention group
Group type: COMPARATOR
Intervention: Theophylline 0 mg/kg (Control)
Number of subjects: 24
Study 2203382 — intervention group
Group type: EXPERIMENTAL
Intervention: Gerovital
Number of subjects: 88
Study 2203382 — intervention group
Group type: EXPERIMENTAL
Intervention: Another procaine preparation
Number of subjects: 88
Study 2203382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 911591 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% plain lignocaine 20 ml
Number of subjects: 15
Study 911591 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lignocaine 20 ml with adrenaline 1:200,000
Number of subjects: 15
Study 29371382 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly intensive inspiratory muscle training (IMT)
Number of subjects: 611
Study 29371382 — intervention group
Group type: COMPARATOR
Intervention: Sham inspiratory muscle training (IMT)
Number of subjects: 611
Study 25724021 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at LI4
Number of subjects: 49
Study 25724021 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic injection without acupuncture
Number of subjects: 49
Study 24012131 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified intervention (N = 371)
Number of subjects: 738
Study 24012131 — intervention group
Group type: COMPARATOR
Intervention: Usual care (N = 367)
Number of subjects: 738
Study 22299093 — intervention group
Group type: EXPERIMENTAL
Intervention: Three different types of implants from three different manufacturers
Number of subjects: 3
Study 22299093 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants loaded after 8 weeks
Number of subjects: 3
Study 20555044 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol 400 microg every 6 h for a maximum of four doses
Number of subjects: 185
Study 20555044 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol 400 microg every 12 h for a maximum of four doses
Number of subjects: 185
Study 20555044 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens of vaginal misoprostol
Number of subjects: 185
Study 19040018 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/m2 bortezomib combined with dexamethasone
Number of subjects: 23
Study 19040018 — intervention group
Group type: COMPARATOR
Intervention: 1.3 mg/m2 bortezomib combined with dexamethasone
Number of subjects: 23
Study 16021483 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil for 30 days
Number of subjects: 30
Study 16021483 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 30 days
Number of subjects: 30
Study 12154491 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical treatment for athlete's foot
Number of subjects: 0
Study 12154491 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic treatment for athlete's foot
Number of subjects: 0
Study 12154491 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 10235351 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic tropisetron 5 mg orally before anesthesia
Number of subjects: 68
Study 10235351 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 68
Study 8916060 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg once daily for 2 weeks
Number of subjects: 53
Study 8916060 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine 250 mg twice daily for 2 weeks
Number of subjects: 53
Study 1763595 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVA using midazolam and alfentanil with flumazenil reversal (n = 15)
Number of subjects: 28
Study 1763595 — intervention group
Group type: COMPARATOR
Intervention: Balanced anaesthesia using midazolam, alfentanil, and nitrous oxide without flumazenil reversal (n = 13)
Number of subjects: 28
Study 6356969 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl
Number of subjects: 36
Study 6356969 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular fentanyl
Number of subjects: 36
Study 27480401 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral micronized progesterone (OMP) 400 mg/day
Number of subjects: 60
Study 27480401 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 24706544 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound simulator
Number of subjects: 50
Study 24706544 — intervention group
Group type: COMPARATOR
Intervention: Cadaveric specimens and plastic models
Number of subjects: 50
Study 24984771 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual simulation training using the ImmersiveTouch simulator
Number of subjects: 20
Study 24984771 — intervention group
Group type: COMPARATOR
Intervention: No training (Control Group B)
Number of subjects: 20
Study 22932279 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate intake from FA-containing prenatal supplement (750 μg/d) plus natural food folate (400 μg/d)
Number of subjects: 75
Study 20437244 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative-free (PF) dorzolamide/timolol
Number of subjects: 261
Study 20437244 — intervention group
Group type: COMPARATOR
Intervention: Preservative-containing (PC) dorzolamide/timolol
Number of subjects: 261
Study 17921832 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine CR
Number of subjects: 41
Study 17921832 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 41
Study 16288184 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium 100 microg/kg
Number of subjects: 22
Study 16288184 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 600 microg/kg
Number of subjects: 22
Study 12060478 — intervention group
Group type: EXPERIMENTAL
Intervention: Product containing active ingredients to restore barrier function and modulate inflammatory response, applied twice a day for one month prior to UVA irradiation.
Number of subjects: 20
Study 12060478 — intervention group
Group type: COMPARATOR
Intervention: UVA irradiation (6 J.cm‐2)
Number of subjects: 20
Study 9973021 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary angioplasty
Number of subjects: 1138
Study 9973021 — intervention group
Group type: COMPARATOR
Intervention: Accelerated tissue-type plasminogen activator (t-PA)
Number of subjects: 1138
Study 9973021 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 1138
Study 7484037 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceleromyography monitoring
Number of subjects: 40
Study 7484037 — intervention group
Group type: COMPARATOR
Intervention: No nerve stimulator
Number of subjects: 40
Study 2187822 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐fenfluramine (15 mg)
Number of subjects: 8
Study 2187822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6138044 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam (15 mg)
Number of subjects: 10
Study 6138044 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 31294589 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive group behavioral treatment (IGBT)
Number of subjects: 29
Study 31294589 — intervention group
Group type: COMPARATOR
Intervention: Waitlist with psychoeducational resources (WLP)
Number of subjects: 29
Study 31294589 — intervention group
Group type: EXPERIMENTAL
Intervention: IGBT
Number of subjects: 29
Study 28637047 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial valve treatment (EBV)
Number of subjects: 64
Study 27488272 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-phase multifaceted intervention including academic detailing with a pharmacist, GP-led medicines reviews, web-based pharmaceutical treatment algorithms, and tailored patient information leaflets
Number of subjects: 196
Study 27488272 — intervention group
Group type: EXPERIMENTAL
Intervention: GP-led medicines reviews with patients present
Number of subjects: 196
Study 27488272 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised academic detailing session
Number of subjects: 196
Study 27488272 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient information leaflets
Number of subjects: 196
Study 27488272 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall experience of the intervention
Number of subjects: 196
Study 27488272 — intervention group
Group type: EXPERIMENTAL
Intervention: Organisational barriers
Number of subjects: 196
Study 24392890 — intervention group
Group type: EXPERIMENTAL
Intervention: pECMO
Number of subjects: 37
Study 24392890 — intervention group
Group type: COMPARATOR
Intervention: cECMO
Number of subjects: 37
Study 18302601 — intervention group
Group type: EXPERIMENTAL
Intervention: Roy Adaptation Model‐based experimental education, exercise and social support programme
Number of subjects: 43
Study 18302601 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 43
Study 15215009 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow-trigger (FT) sensing on Servo 300 ventilator
Number of subjects: 16
Study 15215009 — intervention group
Group type: COMPARATOR
Intervention: Pressure-trigger (PT) sensing on Servo 300 ventilator
Number of subjects: 16
Study 15215009 — intervention group
Group type: COMPARATOR
Intervention: Pressure-trigger (PT) sensing on Servo 900C ventilator
Number of subjects: 16
Study 10689295 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg nefopam as Acupan(R) administered as a 5‐ or 20‐min intravenous infusion
Number of subjects: 0
Study 10689295 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control) administered to subjects during the control phase
Number of subjects: 0
Study 10689295 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro binding assays and antinociceptive tests in rats and mice
Number of subjects: 0
Study 9366277 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril (ACE inhibitor)
Number of subjects: 0
Study 9366277 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (diuretic)
Number of subjects: 0
Study 9366277 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus pravastatin
Number of subjects: 0
Study 9366277 — intervention group
Group type: COMPARATOR
Intervention: Diet plus placebo
Number of subjects: 0
Study 8347851 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF (10 micrograms/kg intravenously over 6 hours)
Number of subjects: 24
Study 8347851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2424471 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation
Number of subjects: 0
Study 2424471 — intervention group
Group type: COMPARATOR
Intervention: Cigarette smoking
Number of subjects: 0
Study 2424471 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking and nutritional supplementation
Number of subjects: 0
Study 30121630 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone treatment for 9 months
Number of subjects: 146
Study 30121630 — intervention group
Group type: COMPARATOR
Intervention: Matched controls (not treated with spironolactone)
Number of subjects: 146
Study 30121630 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone treatment for 9 months (within-person analysis)
Number of subjects: 146
Study 28662715 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification for paranoia (CBM-pa)
Number of subjects: 60
Study 28662715 — intervention group
Group type: COMPARATOR
Intervention: Text-reading control intervention
Number of subjects: 60
Study 25637909 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-session individual and group cognitive behavior therapy (CBT) for anxiety disorders
Number of subjects: 182
Study 24408900 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed consent document with graphics
Number of subjects: 85
Study 24408900 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed consent document without graphics
Number of subjects: 85
Study 24408900 — intervention group
Group type: COMPARATOR
Intervention: Standard consent document with graphics
Number of subjects: 85
Study 24408900 — intervention group
Group type: COMPARATOR
Intervention: Standard consent document without graphics
Number of subjects: 85
Study 21950587 — intervention group
Group type: EXPERIMENTAL
Intervention: Night guard (Group A)
Number of subjects: 105
Study 21950587 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthwash (Group B)
Number of subjects: 105
Study 21950587 — intervention group
Group type: EXPERIMENTAL
Intervention: Night guard and mouthwash (Group C)
Number of subjects: 105
Study 19430060 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Iron polymaltose complex (IPC), n=59
Number of subjects: 118
Study 19430060 — intervention group
Group type: COMPARATOR
Intervention: Oral Ferrous sulfate (FS), n=59
Number of subjects: 118
Study 17088340 — intervention group
Group type: EXPERIMENTAL
Intervention: variable‐flow Nasal Continuous Positive Airway Pressure (NCPAP)
Number of subjects: 13
Study 17088340 — intervention group
Group type: COMPARATOR
Intervention: conventional NCPAP
Number of subjects: 13
Study 17088340 — intervention group
Group type: COMPARATOR
Intervention: nasal cannulae
Number of subjects: 13
Study 15060518 — intervention group
Group type: EXPERIMENTAL
Intervention: L-DOPA (200 mg) and benserazide (50 mg) administered 1 hour before sleeping for 30 days
Number of subjects: 13
Study 15060518 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise program on a manual bicycle ergometer for 45 days (3 times a week)
Number of subjects: 13
Study 11309057 — intervention group
Group type: EXPERIMENTAL
Intervention: Watchful waiting for 12 weeks
Number of subjects: 639
Study 11309057 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors identified
Number of subjects: 639
Study 11309057 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of risk factors
Number of subjects: 639
Study 11309057 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 639
Study 9215056 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anaesthesia with 0.4% oxybuprocaine
Number of subjects: 35
Study 9215056 — intervention group
Group type: COMPARATOR
Intervention: Sub‐Tenon's infiltration with 2% lignocaine
Number of subjects: 35